NCT02418650View on ClinicalTrials.gov

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions

Healthy

Interventions

DRUG

ODM-201 300 mg tablet

DRUG

intravenous14C-ODM-201

DRUG

300 mg 14C-ODM-201 oral solution

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Orion Corporation, Orion Pharma

INDUSTRY